Biodesix, Inc. BDSX 深 沪
交易中 05-20 10:27:36 美东时间
14.04
+0.100
+0.72%
华盛通- 最 高14.04
- 今 开14.04
- 成交量 682股
- 最 低 14.04
- 昨 收 13.94
- 总市值 14.19万
- 52周最高 20.21
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 5.00
- 委 比 98.04%
- 总股本 1.01万
- 历史最高 639.80
- 量 比 0.18
- 振 幅 0.00%
- 历史最低 3.436
- 每 手 1
- 风险率 3.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Biodesix Q1 2026 Earnings Call: Complete Transcript
Biodesix (NASDAQ:BDSX) released first-quarter financial results and hosted an e...
05-05 05:23
Biodesix shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 sales guidance with its midpoint above estimates.
Biodesix shares are trading higher after the company reported better-than-expec...
05-05 04:58
Biodesix Raises FY2026 Sales Guidance from $106.000M-$112.000M to $108.000M-$114.000M vs $108.680M Est
Biodesix (NASDAQ:BDSX) raises FY2026 sales outlook from $106.000 million-$112.000 million to $108.000 million-$114.000 million vs $108.680 million estimate.
05-05 04:02
Biodesix Announces First Quarter 2026 Results and Highlights
Biodesix reported Q1 2026 revenue of $25.6 million, a 42% year-over-year increase, with a 84% gross margin. The company raised its FY 2026 revenue guidance to $108-114 million, reflecting a 25% growth midpoint. Both diagnostic testing and development services saw strong growth, with test volumes up 29% and development revenue doubling. Biodesix also highlighted its recognition as a Top Workplace for the third consecutive year and plans to host a ...
05-04 20:01
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
Biodesix, Inc. (Nasdaq: BDSX) will release its first quarter 2026 financial results on May 4 after market close. Management will host a conference call and webcast at 4:30 p.m. ET that day to discuss results and provide a business update. Listeners can register via the provided link. Analysts can join by dialing (800) 715-9871 (domestic) or +1 (646) 307-1963 (international) with passcode 2430172. Biodesix is a diagnostic solutions company offerin...
04-20 10:00
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
Biodesix, Inc. will present seven abstracts, including two oral sessions, at the AACR Annual Meeting in San Diego, showcasing their expertise in blood- and tissue-based testing for oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing. The presentations highlight advancements in tumor and immune profiling, rapid turnaround times, and novel proteomic and genomic approaches. Biodesix's technologies includ...
04-06 15:43
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
Biodesix的Nodify CDT®测试在一项涉及1,100名患者的回顾性分析中展示了其在肺癌早期检测中的稳定临床表现。该研究发表于《Future Oncology》，表明Nodify CDT®能在4-30毫米肺结节中以高特异性（91-97%）识别肺癌高风险患者。数据跨四个不同临床研究和48家美国临床机构，显示其在真实世界中的高度适用性。专家指出，该测试通过提供可靠的生物标志物检测，有助于临床医生更早确定治疗方案，从而改善患者预后。
03-20 12:06
